Nanobiotix SA (NBTX) - Revenue and Sales Volume

Nanobiotix - graphic logo of issuer NBTX

Nanobiotix S.A. expenses are driven by the progress of clinical trials, independent of economic cycles. The company's sales statistics demonstrate a lack of recurring revenue, where 0.01 represents the current metric. Financial stability is based on external investments, while the unique tumor radio-enhancement method, in alliance with pharma behemoths, minimizes market pressure.

NBTX: Nanobiotix SA Revenue and Sales Volume 07/04/2022 - 11/18/2026

Analytical breakdowns for Nanobiotix S.A.

Comprehensive company analysis:NBTX nanobiotix.com
Original product of Nanobiotix SA

This indicator captures the actual volume of daily cash inflows from the sale of products and services, excluding reporting gaps. By analyzing the company's sales statistics, an investor assesses real consumer demand relative to production capacity. For Nanobiotix S.A. (NBTX), this flow is generated through the commercialization of its radiosensitization platform. Licensing royalties ensure revenue stability and long-term patent protection. Steady growth in this metric confirms the resilience of the business model.